AUS
NZ
UK
CA
USA
IND
Highlights:
Celldex Therapeutics Founder Anthony Marucci made a significant purchase of company shares, acquiring 40% more stock.
Insider transactions in the past year show a trend of more selling than buying, with the largest sale occurring by the Senior VP & Chief Medical Officer.
Insider ownership at Celldex Therapeutics is relatively low, with insiders holding approximately 0.3% of the company’s shares.
Celldex Therapeutics, (NASDAQ:CLDX) a biopharmaceutical company focused on developing therapeutic antibodies, recently saw significant insider activity, with Founder Anthony Marucci purchasing a substantial amount of stock. Marucci bought shares at $26.82 each, increasing his holdings by 40%. This purchase signals confidence from the company’s founder, though it follows a pattern of more selling than buying by insiders in the past year.
The most notable insider sale over the last twelve months was made by Diane Young, the Senior VP and Chief Medical Officer, who sold a large quantity of shares at $35.26 each. This sale, totaling around $1.6 million, occurred at a price significantly higher than the current market price of around $24.98. Although insider selling can sometimes raise concerns, the fact that this sale occurred at a higher price than the current value may not reflect negatively on the company’s outlook.
However, when examining insider ownership, it is noted that Celldex insiders collectively own approximately 0.3% of the company’s shares, valued at around $4.9 million. This relatively low level of insider ownership suggests that management may not have as strong a financial stake in the company compared to shareholders. Higher insider ownership is often seen as a positive indicator of alignment between leadership and shareholders.
While Marucci’s recent purchase provides some reassurance, the broader trend of insider selling, along with the low insider ownership, may leave questions about internal confidence in the company’s future performance. These factors, combined with the risks facing the company, warrant careful observation. Investors may look to future insider transactions and financial reports for more insight into Celldex's potential moving forward.
